🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🚨 Patients w cirrhosis have ⬆️ risk of periop death so preop risk stratification is critical! ✅out this Hepatology Communications Review for everything you need to know re: Assessing the Risk of Surgery in Patients w Cirrhosis 🔑points in🧵below!! #LiverTwitter journals.lww.com/hepcomm/Fullte…

🆕CPG❕ EASL Clinical Practice Guidelines on TIPS ✅Addresses all aspects of #TIPS in patients with #cirrhosis Full text here: bit.ly/4hZuMUK #LiverTwitter EASLnews EASL Education

📜EASL has published its first Clinical Practice Guidelines focused on transjugular intrahepatic portosystemic shunt (TIPS) in patients with cirrhosis. These evidence-based recommendations address key aspects of TIPS, including: ✔️ Patient selection and pre-procedure assessment

🌍 Cross-national insights into primary biliary cholangitis This comparative study explores the clinical and biochemical characteristics of incident and prevalent PBC cases in both Danish and Turkish cohorts. Results highlight shared patterns as well as region-specific

📢ESSENCE out now and it's a game changer for hepatology! GLP-1 RA improves histology AND metabolic health in MASH F2-3 fibrosis: 📍Absolute difference in fibrosis reduction of 15% = NNT 6.7 📍63% resolution of MASH vs 34% placebo. Wauw #LiverTwitter 🔗nejm.org/doi/full/10.10…

🚨 Important Update 🚨 A new version of the EASL Guidelines App is now available! To access the latest features, please delete the old version and reinstall the app from your app store. 🆕 What’s new? ✅ 24 new calculators ✅ Access to EASL policy statements & policy dialogues

🩸 New data add to current evidence on #PlasmaExchange in ACLF: TPE may improve short-term survival in selected patients unresponsive ☞ More work needed to define who benefits & when #LiverTwitter #EASL #INASL #EFCLIF jcehepatology.com/article/S0973-…

📢Great to write this Hepatology Communications review with Matthew Armstrong 💙 & Jonathan G. Stine, MD MSc, FACP 💪We've covered everything you need to know about #Muscle & #MASLD - Insulin resistance - Sarcopenia - Myosteatosis - Impact of weight loss drugs - Benefits of exercise 🔗shorturl.at/aFO1Q

28-31 Mayıs 2025 tarihlerinde Singapur’da düzenlenen International Liver Transplantation Society (ILTS) 2025 Kongresi, “Liver Transplantation’da Geleceği Şekillendiren Yenilikler” temasıyla bu yıl da dünya çapında ses getirdi.

Who has lower probability of recompensation? 1️⃣⬆️ MELD 2️⃣🤕further decompensation before etiological cure 🤔 Point of non return? 3️⃣⬆️ BMI 🤔 underlying MASLD? More data are coming AASLD … Thomas Reiberger The Baveno Cooperation: an EASL Consortium

It's finally here! Consensus #ACLF & #cirrhosis organ failure definitions. Gastroenterology ⤵️ pubmed.ncbi.nlm.nih.gov/40499736/ Why? We need to speak the same language re #ACLF for #transplant/new Rx dev How? Multi-country consensus panels Result? Harmonized definitions &  research agenda

🎉 New review out 🥳 Ilkay Ergenc and The Liver Dude explore the therapeutic pipeline for difficult-to-treat autoimmune hepatitis (AIH) 🤔 — from thiopurine optimisation to biologics and beyond, with a fantastic stepwise approach 🤓 💊 ! Check it out 🫵 !

📢 Harika haber! Hepatology Forum’un 2024 Impact Faktörü %75 artarak 2.1’e çıktı! 🌍 Artık Q3 dergiler arasındayız. 🇹🇷 Türkiye’deki medikal dergiler arasında 3. sıradayız. Teşekkürler hepatoloji camiası!

Today, NEJM reports that Efruxifermin (an FGF21 agonist) is the first drug to reduce fibrosis in compensated cirrhosis due to NASH. This effect is seen after 96 weeks, so patience is key. Could combining Semaglutide make it even more powerful?

📢 NEW in HEPATOLOGY Journal 📢Jasmohan Bajaj & #VCU, Richmond VAMC and Mayo Clinic co-authors find smartphone app, designed to help people with cirrhosis manage their health at home, shows promise in reducing avoidable hospital visits. bit.ly/4lNtTB9

Expanding the indication of living donor liver transplantation to recipients with portal vein thrombosis: Clinical advances and ongoing challenges journals.lww.com/lt/citation/99…

Long-term Efficacy and Safety of Selective PPARδ Agonist Seladelpar in Primary Biliary Cholangitis: ASSURE Interim Study Results Levy, et al. 📕 doi.org/10.14309/ajg.0… Cynthia Levy, MD Palak Trivedi Christopher Bowlus, MD Maria Carlota Londoño Aliya Gulamhusein Andreas Kremer Millie Long Jasmohan Bajaj

Enhancement of Cirrhosis Mortality Prediction by Including Hepatic Encephalopathy to MELD 3.0 in a National Veteran Cohort Silvey, et al. 📕 doi.org/10.14309/ajg.0… Nilang Patel, MD, MS, FASN Jacqueline O'Leary Jasmohan Bajaj Millie Long

⏱️Dünya Hepatit Günü’nde Hocalarımızdan Size Mesaj Var! ⏱️On World Hepatitis Day, Our Professors Have Messages For You! #TKAD #28TemmuzDünyaHepatitGünü #KaraciğerSağlığı #Sağlık